Inozyme Pharma (NASDAQ:INZY) Announces Quarterly Earnings Results

Inozyme Pharma (NASDAQ:INZY) posted its earnings results on Tuesday. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.05, Zacks reports.

Inozyme Pharma Stock Down 3.1 %

Shares of INZY stock traded down $0.13 during trading on Thursday, reaching $4.10. The company’s stock had a trading volume of 516,644 shares, compared to its average volume of 418,649. Inozyme Pharma has a one year low of $2.71 and a one year high of $7.80. The business has a fifty day moving average price of $5.15 and a 200-day moving average price of $4.93. The company has a market cap of $257.19 million, a price-to-earnings ratio of -2.90 and a beta of 1.54. The company has a quick ratio of 9.84, a current ratio of 9.84 and a debt-to-equity ratio of 0.48.

Wall Street Analyst Weigh In

INZY has been the topic of several recent analyst reports. Wedbush reiterated an “outperform” rating and set a $12.00 target price (down from $15.00) on shares of Inozyme Pharma in a report on Tuesday. Jefferies Financial Group reiterated a “buy” rating and issued a $17.00 price objective (up from $16.00) on shares of Inozyme Pharma in a research report on Tuesday, August 13th. Stifel Nicolaus assumed coverage on shares of Inozyme Pharma in a research note on Thursday, September 12th. They issued a “buy” rating and a $16.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Inozyme Pharma in a report on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Inozyme Pharma in a report on Wednesday. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Inozyme Pharma has an average rating of “Buy” and a consensus target price of $15.71.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.